News
WHO public consultation on draft target product profiles (TPPs) for needed antibacterial agents
The global increase in antimicrobial resistance is limiting available treatment options for many bacterial infections, and the current clinical pipeline for new antibacterial agents is not sufficient to cover future public health needs. The WHO is therefore developing target products profiles (TPPs) for needed antibacterial agents, providing the public health perspective to funders and developers on the performance and operational characteristics desired of new needed therapeutic products.
Veelbelovende samenwerking antibiotica en immuunsysteem
In Europa overlijden jaarlijks 25.000 mensen aan de gevolgen van een infectie met bacteriën die resistent zijn tegen antibiotica. De ontwikkeling van nieuwe antibiotica verloopt moeizaam, maar onderzoek van het UMC Utrecht biedt nieuwe mogelijkheden. Promovenda Dani Heesterbeek en hoogleraar Suzan Rooijakkers vertellen in De Nieuws BV over het onderzoek.
FDA approves new antibiotic to treat community-acquired bacterial pneumonia
The U.S. Food and Drug Administration today approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia.
GNA NOW kicks off its battle against antimicrobial resistance
On July 1st, a new partnership launched in the fight against antimicrobial resistance. GNA NOW (Gram-Negative Antibacterials NOW) will work on the development of novel antibacterial agents against antimicrobial resistance in gram-negative bacteria. The project is a multi-stakeholder effort, led by Evotec and managed by Lygature, with other partners from academia, industry and SMEs: Nosopharm, BIOASTER, Helmholtz Centre for Infection Research, North Bristol National Health Service Trust, University of Liverpool, Inserm, Erasmus Medical Center, Medical University of Vienna, and Fraunhofer IME.
FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis
Pretomanid, developed by the non-profit TB Alliance, has received U.S. approval in combination regimen with bedaquiline and linezolid for people with XDR-TB or treatment-intolerant/non-responsive MDR-TB.
EU awards EUR 18 million for research into new antibiotics
An international consortium of research groups aims to develop novel antibiotics against the tuberculosis bacteria and two other deadly bacteria. The European Union has awarded a total of EUR 18 million to the RespiriTB and RespiriNTM projects. Researchers from the Leiden University Medical Centre (LUMC) will be taking part in the study, that is set to last six years.